-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The number of patients with eye diseases in China is relatively large.
According to the Guoyuan Securities Research Report, taking common eye diseases as an example, the number of adolescent myopia population is estimated to be about 100 million, the adult population of myopia is 450 million, and the macular fundus disease is about 64 million
.
As China’s aging rate increases, work intensity increases, and life>
.
It is worth mentioning that in this context, while the ophthalmology market has seen a rapid growth trend, a large number of companies have continued to improve their performance
.
On October 25, Aier Ophthalmology announced its three quarterly results announcement
.
The announcement showed that operating income in the first three quarters was 11.
596 billion yuan, a year-on-year increase of 35.
38%; net profit was 2.
003 billion yuan, a year-on-year increase of 29.
59%
.
Among them, the net profit in the third quarter was 888 million yuan, a year-on-year increase of 2.
05% and a quarter-on-quarter increase of 40.
5% compared to the second quarter
.
On the whole, the operating income of Aier Ophthalmology in the first three quarters increased by 35.
38% compared with the same period of the previous year, which greatly exceeded the performance of the same period in 2020, and was close to reaching the top three levels in the past ten years
.
Regarding the surge in performance, Aier Ophthalmology said that it was mainly due to the expansion of the company's business scale, increased brand influence, and upgrade of medical consumption, which led to the increase in the volume of diagnosis and treatment and surgery
.
On October 24, the 2021 third quarter report of Guangzheng Ophthalmology showed that the company's main operating income was 779 million yuan, a year-on-year increase of 25.
96%; the net profit attributable to the parent company was 45.
997 million yuan, a year-on-year increase of 51.
74%
.
It is understood that Guangzheng Ophthalmology is mainly engaged in the investment and management of eye hospitals
.
As a professional ophthalmology chain medical company, it has been focusing on the ophthalmic medical service market in large and medium-sized cities
.
At present, 13 professional eye hospitals have been opened in 10 central cities including Shanghai, Chengdu, Chongqing, Zhengzhou, Nanchang, Hohhot, Jinan, Qingdao, Wuxi, Yiwu, etc.
, forming a mature platform hospital replication chain development model and supporting management system
.
On October 28, Aibo Medical, an ophthalmology platform company, will also announce its third quarterly report
.
According to the 2021 semi-annual results disclosed by Aibo Medical on August 17, it achieved revenue of 206 million yuan, a year-on-year increase of 99.
16%; net profit attributable to shareholders of listed companies was 91.
4 million yuan, a year-on-year increase of 143.
61%.
It is believed that in the three quarterly reports, Aibo Medical's performance may also reach new highs
.
In general, with the continuous increase in the popularity of the ophthalmic gold track, the performance of related pharmaceutical companies continues to obtain new breakthroughs, and the track is also becoming one of the more prominent subdivisions in the pharmaceutical industry
.
The industry predicts that in the future, companies with specialized promotion advantages will have higher voice and channel advantages.
With the continuous rise of domestic companies, the pace of substitution of imports will also accelerate, and the future market pattern may change
.
However, it should be noted that in view of the low penetration rate of the treatment of diseases such as cataracts, glaucoma, and refractive correction, the industry predicts that there will be at least two times more room for growth in the diagnosis and treatment of eye diseases in China in the future.
By 2025, the scale of China's ophthalmology market Or at least more than 310 billion, this is undoubtedly a big mouth-watering cake, and it will also attract more and more companies into the game
.
According to the Guoyuan Securities Research Report, taking common eye diseases as an example, the number of adolescent myopia population is estimated to be about 100 million, the adult population of myopia is 450 million, and the macular fundus disease is about 64 million
.
As China’s aging rate increases, work intensity increases, and life>
.
It is worth mentioning that in this context, while the ophthalmology market has seen a rapid growth trend, a large number of companies have continued to improve their performance
.
On October 25, Aier Ophthalmology announced its three quarterly results announcement
.
The announcement showed that operating income in the first three quarters was 11.
596 billion yuan, a year-on-year increase of 35.
38%; net profit was 2.
003 billion yuan, a year-on-year increase of 29.
59%
.
Among them, the net profit in the third quarter was 888 million yuan, a year-on-year increase of 2.
05% and a quarter-on-quarter increase of 40.
5% compared to the second quarter
.
On the whole, the operating income of Aier Ophthalmology in the first three quarters increased by 35.
38% compared with the same period of the previous year, which greatly exceeded the performance of the same period in 2020, and was close to reaching the top three levels in the past ten years
.
Regarding the surge in performance, Aier Ophthalmology said that it was mainly due to the expansion of the company's business scale, increased brand influence, and upgrade of medical consumption, which led to the increase in the volume of diagnosis and treatment and surgery
.
On October 24, the 2021 third quarter report of Guangzheng Ophthalmology showed that the company's main operating income was 779 million yuan, a year-on-year increase of 25.
96%; the net profit attributable to the parent company was 45.
997 million yuan, a year-on-year increase of 51.
74%
.
It is understood that Guangzheng Ophthalmology is mainly engaged in the investment and management of eye hospitals
.
As a professional ophthalmology chain medical company, it has been focusing on the ophthalmic medical service market in large and medium-sized cities
.
At present, 13 professional eye hospitals have been opened in 10 central cities including Shanghai, Chengdu, Chongqing, Zhengzhou, Nanchang, Hohhot, Jinan, Qingdao, Wuxi, Yiwu, etc.
, forming a mature platform hospital replication chain development model and supporting management system
.
On October 28, Aibo Medical, an ophthalmology platform company, will also announce its third quarterly report
.
According to the 2021 semi-annual results disclosed by Aibo Medical on August 17, it achieved revenue of 206 million yuan, a year-on-year increase of 99.
16%; net profit attributable to shareholders of listed companies was 91.
4 million yuan, a year-on-year increase of 143.
61%.
It is believed that in the three quarterly reports, Aibo Medical's performance may also reach new highs
.
In general, with the continuous increase in the popularity of the ophthalmic gold track, the performance of related pharmaceutical companies continues to obtain new breakthroughs, and the track is also becoming one of the more prominent subdivisions in the pharmaceutical industry
.
The industry predicts that in the future, companies with specialized promotion advantages will have higher voice and channel advantages.
With the continuous rise of domestic companies, the pace of substitution of imports will also accelerate, and the future market pattern may change
.
However, it should be noted that in view of the low penetration rate of the treatment of diseases such as cataracts, glaucoma, and refractive correction, the industry predicts that there will be at least two times more room for growth in the diagnosis and treatment of eye diseases in China in the future.
By 2025, the scale of China's ophthalmology market Or at least more than 310 billion, this is undoubtedly a big mouth-watering cake, and it will also attract more and more companies into the game
.
